Thus, AMPK activation by obestatin does not act as a negative regulator of mTOR, which is in clear contrast to other anabolic inputs, such as insulin in DMD myotubes (Figure 4D). This evidence concerns the gene PRKAA1 and Duchenne muscular dystrophy.